ID   PT1590
AC   CVCL_0C61
SY   PT-1590
DR   cancercelllines; CVCL_0C61
DR   GEO; GSM1264065
DR   GEO; GSM1264066
DR   GEO; GSM1264067
DR   GEO; GSM1264078
DR   GEO; GSM1264079
DR   GEO; GSM1264080
DR   GEO; GSM1264081
DR   GEO; GSM1264091
DR   GEO; GSM1264107
DR   GEO; GSM1264108
DR   GEO; GSM1264109
DR   GEO; GSM1264120
DR   GEO; GSM1264121
DR   GEO; GSM1264122
DR   GEO; GSM1264123
DR   GEO; GSM1264133
DR   Progenetix; CVCL_0C61
DR   Wikidata; Q54948650
RX   PubMed=11156375;
RX   PubMed=25070024;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Met246Ile (c.738G>A); ClinVar=VCV000480961; Zygosity=Unspecified (PubMed=11156375).
CC   Caution: TP53 mutation indicated (PubMed=11156375) to change a His-176 into Arg, but the DNA change corresponds to the mutation reported in this entry.
CC   Derived from site: In situ; Esophagus; UBERON=UBERON_0001043.
DI   NCIt; C4025; Esophageal adenocarcinoma
DI   ORDO; Orphanet_99976; Adenocarcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0C60 ! LN1590
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 19-12-24; Version: 11
//
RX   PubMed=11156375;
RA   Hosch S., Kraus J., Scheunemann P., Izbicki J.R., Schneider C.,
RA   Schumacher U., Witter K., Speicher M.R., Pantel K.;
RT   "Malignant potential and cytogenetic characteristics of occult
RT   disseminated tumor cells in esophageal cancer.";
RL   Cancer Res. 60:6836-6840(2000).
//
RX   PubMed=25070024; DOI=10.1007/s00423-014-1235-1;
RA   Drenckhan A., Grob T., Dupree A., Dohrmann T., Mann O., Izbicki J.R.,
RA   Gros S.J.;
RT   "Esophageal carcinoma cell line with high EGFR polysomy is responsive
RT   to gefitinib.";
RL   Langenbecks Arch. Surg. 399:879-888(2014).
//